Paper37815596
Immunotherapies landscape and associated inhibitors for the treatment of cervical cancer.
Yadav A and 2 others. Med Oncol, 2023. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Immunotherapies landscape and associated inhibitors for the treatment of cervical cancer. Papers, record 37815596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37815596
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Immunotherapies landscape and associated inhibitors for the treatment of cervical cancer.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Uterine Cervical Neoplasms | Major topic |
| Humans | |
| Female | |
| Immunotherapy | |
| Combined Modality Therapy | |
| Human Papillomavirus Viruses |
Source PubMed
References103
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27171673 | Advances in diagnosis and treatment of metastatic cervical cancer. | J Gynecol Oncol | 2016 | https://conductscience.org/library/papers/27171673 | PubMed |
| 2 | 17704786 | Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. | Nat Med | 2007 | https://conductscience.org/library/papers/17704786 | PubMed |
| 3 | 20411564 | Modulating numbers and phenotype of CD8+ T cells in secondary immune responses. | Eur J Immunol | 2010 | https://conductscience.org/library/papers/20411564 | PubMed |
| 4 | 30943124 | Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/30943124 | PubMed |
| 5 | 29095678 | Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/29095678 | PubMed |
| 6 | 29538258 | A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer. | Int J Gynecol Cancer | 2018 | https://conductscience.org/library/papers/29538258 | PubMed |
| 7 | 31428574 | Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System. | Front Oncol | 2019 | https://conductscience.org/library/papers/31428574 | PubMed |
| 8 | 7622099 | New gynecologic cancer staging. | Gynecol Oncol | 1995 | https://conductscience.org/library/papers/7622099 | PubMed |
| 9 | 18980286 | HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. | Cancer | 2008 | https://conductscience.org/library/papers/18980286 | PubMed |
| 10 | 10202165 | Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. | N Engl J Med | 1999 | https://conductscience.org/library/papers/10202165 | PubMed |
| 11 | 14985791 | Comparison of HPV DNA vaccines employing intracellular targeting strategies. | Gene Ther | 2004 | https://conductscience.org/library/papers/14985791 | PubMed |
| 12 | 10822298 | Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. | Gene Ther | 2000 | https://conductscience.org/library/papers/10822298 | PubMed |
| 13 | 17341658 | CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. | Carcinogenesis | 2007 | https://conductscience.org/library/papers/17341658 | PubMed |
| 14 | 25752814 | Human papillomavirus molecular biology and disease association. | Rev Med Virol | 2015 | https://conductscience.org/library/papers/25752814 | PubMed |
| 15 | 23615841 | Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. | Cancer Immunol Immunother | 2013 | https://conductscience.org/library/papers/23615841 | PubMed |
| 16 | 18483387 | Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/18483387 | PubMed |
| 17 | 26901118 | Current state in the development of candidate therapeutic HPV vaccines. | Expert Rev Vaccines | 2016 | https://conductscience.org/library/papers/26901118 | PubMed |
| 18 | 20170766 | Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. | Vaccine | 2010 | https://conductscience.org/library/papers/20170766 | PubMed |
| 19 | 19890126 | Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19890126 | PubMed |
| 20 | 762493 | Identification of a novel cell type in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new surface markers, and maintenance in vitro. | J Exp Med | 1979 | https://conductscience.org/library/papers/762493 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41234865 | CC/CXC chemokine risk signature at single-cell resolution: a machine learning model for precision stratification in cervical cancer. | Transl Cancer Res | 2025 | https://conductscience.org/library/papers/41234865 | PubMed |
| 40227870 | Role of Fascin-1 in cervical cancer metastasis via Wnt/β-catenin pathway activation. | Biomol Biomed | 2025 | https://conductscience.org/library/papers/40227870 | PubMed |
| 40124621 | TGF-β-mediated activation of fibroblasts in cervical cancer: implications for tumor microenvironment and prognosis. | PeerJ | 2025 | https://conductscience.org/library/papers/40124621 | PubMed |
| 38840928 | Immune cell infiltration and prognostic index in cervical cancer: insights from metabolism-related differential genes. | Front Immunol | 2024 | https://conductscience.org/library/papers/38840928 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GZMH | 2999 | PubTator's text mining | https://conductscience.org/library/genes/2999 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37815596
GET https://conductscience.org/api/papers/v1/37815596/references?page=2